Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AAV-CAMKII-CofilinS3A is a viral gene therapy construct designed for research purposes to express a constitutively active form of cofilin (CofilinS3A) specifically in excitatory neurons. The construct utilizes an adeno-associated virus (AAV) vector and the CaMKII (calcium/calmodulin-dependent protein kinase II) promoter to drive expression. The S3A mutation (Serine to Alanine at position 3) prevents the inhibitory phosphorylation of cofilin, resulting in a protein that is persistently active in regulating actin dynamics. In preclinical studies, particularly those involving sleep disruption and Alzheimer's disease models, this tool is used to investigate how activated cofilin contributes to synaptic loss, neural injury, and impaired calcium clearance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AAV-CAMKII-CofilinS3A.